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Use of herbal medicine in the treatment of liver cancer has a long tradition. The compounds derived from the herb and herbal
composites are of considerable interest among oncologists. In the past, certain herbal compounds and herbal composite formulas
have been studied through in vitro and in vivo as an anti-hepatocellular carcinoma (HCC) agent, enhancing our knowledge
about their biologic functions and targets. However there is a signiﬁcant distinction between the herbal medicine and the herbal
production even though both are the plant-based remedies used in the practice. In this article, for the sake of clarity, the eﬀective
herbal compounds and herbal composite formulas against HCC are discussed, with emphasizing the basic conceptions of herbal
medicine in order to have a better understanding of the prevention and treatment of HCC by herbal active compounds and herbal
composite formulas.
1.Introduction
1.1. Herbal Medicine. Generally, the description of herbal
medicine is the use of medicinal herbs, preparation made
from a plant or plants, to prevent and treat diseases and
ailments or to promote health and healing. However, it
is important to distinguish “herbal medicine” and “herbal
production”, which is often overlooked [1, 2]. There is a
signiﬁcant distinction between the herbal medicine and the
herbalproduction,botharetheplant-basedremediesusedin
the practice. Herbal production is the conventional medicine
with deﬁnite ingredient(s) and deﬁnite pharmacological
eﬀects when the “plant drug” is for medical use. Whereas,
the use of herbs in herbal medicine divorced from the
context of the so-called “scientiﬁc information” and thus not
as strongly scientiﬁcally validated is a speciﬁc discipline of
herbal medicine that provides the therapeutic understanding
of the medicinal use of herbs [3, 4].
A good example of herbal medicine is “Chinese herbal
medicine”,onebranchoftraditionalChinesemedicinewhich
focuses on naturalism and holistic health that can be traced
back as far as 2100 BC in ancient China [5]. In Chinese
herbal medicine, the herbs are classiﬁed according to their
properties. The use of speciﬁc herb(s) to treat diseases
depends on the sign and symptom of patients. The herbalists
believe that illness is an imbalance status of the body, and
the herbs, based on their various characteristics which are in
the accordance with the law of nature, can neutralize the sign
and the symptom thereby keep an overall balanced status in
patient’s body [6]. Similar to Chinese herbal medicine, is the
Ayurvedic alternative herbal medicine of India, the balance
between agni (representing strength, health and innovation)
and ama (representing weakness, disease and intoxication) is
also emphasized. Therefore, herbal medicine is a preparation
made from a plant or plants and used for any of such
purposes, and the biological ingredients of herbal remedies
are extracted from natural substances such plants, animal
parts, shells, insects and even stones and minerals.
In general, the herbs used in herbal medicine often result
from a combination of herbs with multiple ingredients,
called “herbal composite formula”, to ensure eﬀective actions
on multiple targets simultaneously. Contrary to Western
medicine that prefers the analytical approach, most com-
posite formulas in Chinese herbal medicine are empirically
based and the principles underlining the composite formula
are relatively simple; however, not as strongly deﬁned and
can vary among herbalists. A “food model” could be a
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the composite formula. Foods are complex and contain
many diﬀerent constituents. The furnished materials are
used by body to nourish, support and reproduce its vital
activities, while the wastes and some toxic materials are
eliminated by the body itself. The rule of the composite
formula and the dosage for an individual with speciﬁc signs
and symptoms is also in the same way similar to the dosage
of materials to treat marasmus and diet materials to treat
obesity.Althoughthechoiceofherbsor“compositeformula”
forsomespeciﬁcsignsandsymptomsmayrepresentinparta
trend towards mysticism and thus highly variable, the fact is
that some herbal drugs contain ingredients that speciﬁcally
treat diseases. These biological ingredients extracted from
natural substances result in multiple eﬀective actions on
diﬀerent biological molecular targets.
Modern biomolecular science has contributed to the
interpretation of these multiple eﬀective actions of herbs,
and some important properties such as anti-virus, anti-
inﬂammatory and anticancer have been recognized. As more
information is becoming available, some “herbal drugs” are
identiﬁed for the eﬀects against hepatocellular carcinomas
(HCC). This aim of this review article is to present the
current state of herbal medicine as a chemopreventitive and
chemotherapeutic agent in HCC.
1.2. HCC and Herbal Medicine. HCC is the ﬁfth most
common malignancy worldwide, and with a continuously
increasing incidence [7, 8] .T h r e ec u r a t i v em e t h o d sa r e
currently available: orthotopic liver transplantation (OLT),
surgical resection and local destruction (LD). However, only
few patients qualify for the “curative therapies” because
these strategies depend largely on the extent and location
of the tumor and the underlying liver disease such as
cirrhosis. Despite these curative options, the recurrence
r a t em a yb ea sh i g ha s5 0 %a t2y e a r s[ 9, 10]. Therefore,
prevention of recurrent HCC after (or before) successful
curative therapeutic interventions needs to be improved
i no r d e rt om a k ea ni m p a c to nl o n g - t e r ms u r v i v a lo f
these patients. Many adjuvant treatments such as trans-
arterial chemo-embolization (TACE), anti-viral treatments
and immunotherapy have been used but never conﬁrmed
if positive [11–14]. Palliative treatments for HCC are
indicated if there is no curative treatment option, four
palliative treatments are transarterial chemo-embolization,
systemic chemotherapy, interferon and hormonotherapy
[15]. However, palliative therapy of patients with HCC
remains challenging as HCC is highly resistant to systemic
therapies. Importantly, the incidence still nearly equals the
mortality rate and more than 80% of patients present with
advanced disease [15]. The overall disappointing results of
both curative therapies and palliative treatments in advanced
HCC patients support the research for other more active
and speciﬁc treatments to be administered alone or in
combination with the current therapy.
Currently, few medical interventions have been thor-
oughly tested in HCC, in contrast with the many tested
in other highly prevalent cancers, such as lung, breast
and colorectal cancer [16, 17]. There is an urgent need
for new active and well-tolerated treatments to improve
survival among patients with advanced HCC (palliative
setting) and to increase long lasting remission after curative
treatments (adjuvant setting). Studies, especially in China,
on the prevention and treatment using herbal medicine
againstHCChavebeenaccumulatedduringthepastdecades.
Herbal compounds could aﬀect all phases of HCC, includ-
ing initiation, promotion and progression [18, 19]. The
active development of innovative therapeutic approaches
and molecularly targeted agents using herbal medicine could
oﬀer an opportunity to study the agents in HCC and gives
new hope for the future. Despite massive investigation and
eﬀort, no such herb-drug for HCC treatment has been
licensed to date. Actually, herbs are regulated in the USA
under Dietary Supplement Health and Education Act only
as “dietary supplements”, as opposed to the Chinese category
“traditional Chinese medicine”. Regarding the current use of
herbs,manyquestionscannotbeanswereddeﬁnitivelybythe
available scientiﬁc data. In some instances enough research
has not been performed, and in others the ﬁnal end point of
the research is ﬂawed.
2. Methods
In this article, for the sake of clarity, we divided the
herbal medicine into eﬀective herbal compounds and herbal
composite formula to discuss their anticancer properties
against HCC. Several reviews have provided major contri-
butions to the current knowledge on the herbal medicines
for treatment of liver ﬁbrosis and cancer [20–23]. The
basic concepts of these “botanical drugs” are emphasized in
order to have a better understanding of the prevention and
treatment of HCC by herbal active compounds and herbal
composite formula. The reports from both Chinese and
English language are reviewed to provide a full picture of the
progression of the use of herbal medicine against HCC. The
English literature searches were conducted through Medline,
Embase, Science Citation Index, Current Contents, PubMed
databases, as well as relevant papers from integrative and
complementary medicine journals, such as Evidence Based
ComplementaryandAlternativeMedicine,untilJanuary2009.
The outline of articles reviewed is presented in a Quality
of Reporting of Meta-Analysis (QUORUM) ﬂow chart
showing the number of studies screened and included in
the meta-analysis (Figure 1)[ 24]. Search items were “herb”,
“anticancer mechanism”, “traditional Chinese medicine”,
“hepatoma”, “hepatocellular carcinoma” and “hepatocellular
adenocarcinoma”. Restrictions were placed on language of
publication, and only English was included. Studies lacking
controls were excluded. Case reports were excluded. The
relevant Chinese literature searches were carried out through
Wanfang data until January 2009 using database of China
Medical Association Journals (CMAJ), which is a portal to
medicalresearchmaterialspublishedinChina.Theexclusion
and inclusion for extracted data from literatures were same
as that in PubMed. These restrictions were placed in order to
haveconsistencyamongthereportsreviewed.Theaimofthis
review was to evaluate the current literature for the eﬃcacyEvidence-Based Complementary and Alternative Medicine 3
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Figure 1: QUORUM algorithm of review of the herbal medicine publications and abstracts.
and safety of current herbal compounds in the treatment of
hepatocellular cancer.
2.1. Herbal Compounds. There are a number of molecular
compounds derived from the herbs that have been proven
to be eﬀective against HCC. Modern research is conﬁrming
that many compounds are active at some molecular targets
which are being sought to ﬁnd out potential newer gen-
eration “targeted” biological response modiﬁer drugs [25,
26]. These herbal compounds have been shown to engage
various molecular targets related HCC carcinogenesis and
chemoprevention, which have been identiﬁed by laboratory
research ﬁndings and clinical observations. These molecular
compounds represent an enormous and almost untapped
resource for HCC treatment (Figure 2). Some of the herbal
compounds are discussed and summarized in Table 1.
2.1.1. Curcumin. Curcumin (diferuloylmethane), a com-
pound extracted from Curcuma aromatica widely used as a
spice and coloring agent in food, possesses potent antiox-
idant, anti-inﬂammatory and anticarcinogenic properties.
The anticarcinogenic property has been widely studied
in various cancers [27]. Regarding HCC, three important
properties of curcumin have been studied: anti-HCC; anti-
angiogenesis of HCC; and anti-metastatic activity of HCC.
Chuang et al. investigated the eﬀect of curcumin on
a HCC mouse model induced by N-diethylnitrosamine
(DEN). They found that curcumin can inhibit eﬀectively
DEN-induced hepatocarcinogenesis in the C3H/HeN mice.
The hepatic tissue from the DEN-treated mice showed a
remarkable increase in the levels of p21(ras), expression
of proliferating cell nuclear antigen (PCNA) and CDC2
proteins, while curcumin reversed the levels of all these
biological markers. Another study performed by the same
research group showed that curcumin can also suppress
eﬀectively DEN-induced liver inﬂammation and hyperplasia
in a rat HCC model. Immunoblotting analysis showed that
curcumin inhibits DEN-mediated the increased expression
of oncogenic p21(ras), p53 proteins, PCNA, cyclin E, factor
NF-κ and p34(cdc2), but not Cdk2, c-Jun and c-Fos [28,
29]. Yoysungnoen et al. evaluated the eﬀect of curcumin
and tetrahydrocurcumin on tumor angiogenesis of HCC
mice. Human HCC cell line (HepG2) inoculated onto a
dorsal skin-fold chamber of male BALB/c nude mice, and
curcumin and tetrahydrocurcumin were fed oral daily at
300 and 3000mgkg−1. The tumor microvasculature was
observed using ﬂuorescence videomicroscopy and capillary
vascularity (CV) was measured. They found that treat-
ment with curcumin and tetrahydrocurcumin resulted in
signiﬁcant decrease in the CV. The anti-angiogenic eﬀects
of curcumin and tetrahydrocurcumin were found to be
dose-dependent. They concluded that the anti-angiogenic
properties of curcumin and tetrahydrocurcumin represent a
common potential mechanism for their anti-cancer actions
[30–32].
Curcumin has also been shown to have potent anti-
metastatic activity. Ohashi et al. analyzed the anti-metastatic
mechanism using an orthotopic implantation HCC model
with CBO140C12 cells. They found that daily oral admin-
istration of curcumin suppressed intrahepatic metastasis of
orthotopic implanted HCC cells. They further examined the
eﬀect of curcumin on the metastatic properties in vitro, the
results indicated that curcumin signiﬁcantly inhibited adhe-
sion and haptotactic migration to ﬁbronectin and laminin
thereby inhibiting tumor cells through Matrigel-coated
ﬁlters [33]. An in vitro s t u d yc a r r i e do u tb yL i ne ta l .a l s o
showed that curcumin could be a potential anti-metastatic4 Evidence-Based Complementary and Alternative Medicine
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Figure 2: Summary results of the reported chemopreventitive eﬀects of herbal compounds and herbal composite formulas.
Table 1: Summary of anti-HCC herbal compounds.
Compounds Possible mechanisms of anti-HCC References
Curcumin
Inhibits proliferation; induces apoptosis; inhibits p21(ras), PCNA, cyclin E, factor
NF-κ and p34(cdc2); anti-angiogenesis; inhibits MMP-9 secretion; inhibits histone
deacetylase; enhances P21(WAF1/CIP1) protein; elevates mitochondrial membrane
potential; attenuates ROS
[27–40]
Resveratrol
Inhibits proliferation; induces apoptosis; downregulates Bcl-2 and upregulates Bax
expression; reduces ROS; induces cell-cycle arrest in G1 and G2/M phases;
modulates NO/NOS; increases gap-junctional intercellular communication; sharps
increment of the mitochondria membrane potential; inhibits TNF-alpha-mediated
MMP-9 expression; suppresses the ROS-potentiated invasion.
[41–51]
Silibinin
Causes G1 arrest; induces Kip1/p27; decreases cyclin D1, cyclin D3, cyclin E,
cyclin-dependent kinase (CDK)-2, and CDK4; downregulates metalloproteinase-2;
increases acetylation of histone H3 and H4; inhibits cell proliferation; inhibits NO
production and of ERK 1/2 cascade.
[52–59]
Tanshinone
IIA
Induces apoptosis; induces cell arrested in G(0)/G(1); downregulates bcl-2 and
c-myc; upregulates fas, bax, p53; inhibits DNA synthesis. [60–69]
agent against HCC, they found that curcumin, at 10μM,
inhibited 17.4 and 70.6% of cellular migration and invasion
of SK-Hep-1 cells, a highly invasive SK-Hep-1 cell line of
humanHCC. This anti-metastatic eﬀectis associated withits
inhibitory action on MMP-9 secretion [34]. There are also a
number of studies for exploring the mechanism of curcumin
against HCC. Lv et al. reported that curcumin can inhibit
the level of histone deacetylase, enhance the expression of
P21(WAF1/CIP1) protein and mRNA in HepG2 cells. They
concluded that inhibiting histone deacetylase and increasingEvidence-Based Complementary and Alternative Medicine 5
P21 may be one of the possible mechanisms of curcumin
against HCC [35]. Cao et al. demonstrated that HepG2 cells
treated with curcumin showed a transient elevation of the
mitochondrial membrane potential, followed by cytochrome
c release into the cytosol and disruption of DeltaPsim.
Apoptosis was detected after curcumin treatment but the
expression of Bcl-2 remained unchanged. They conclude
that mitochondrial hyperpolarization is a prerequisite for
curcumin-induced apoptosis in HepG2 cells [36, 37]. Chan
et al. investigated the eﬀect of curcumin on methylglyoxal-
induced apoptotic events in HepG2 cells. In contrary, they
report that curcumin signiﬁcantly attenuates methylglyoxal-
induced reactive oxygen species (ROS) formation thereby
prevented cell apoptosis and apoptotic biochemical changes
such as mitochondrial release of cytochrome c, caspase-
3 activation, and cleavage of PARP (poly [ADP-ribose]
polymerase) [38].
Although numerous in vitro and animal studies have
shown that curcumin exhibits signiﬁcant chemopreventitive
eﬀects and thus reported anti-HCC eﬀect, the exact mech-
anism is largely unknown. The current reason for this lack
of understanding comes from the fact that Curcumin is
a complex herb made up of many potential active agents,
Curcuma aromatica, Curcuma longa and curcumin oil to
name a few, all of which have not been deﬁned as to where
the most active agent(s) are eﬀective in chemoprevention.
In addition, poor systemic absorption of curcumin is still a
major obstacle for its application [39, 40].
2.1.2. Resveratrol. Resveratrol, a polyphenol found in grape
skins, peanuts, berries and red wine, has been shown to
possess potent growth inhibitory eﬀects against various
human cancer cells including HCC. Resveratrol can be
absorbed rapidly and accumulate in the liver. Lancon et
al. studied the absorption and the eﬄux of resveratrol in
the HepG2 cells. They found that resveratrol was rapidly
conjugated and it entirely metabolized at 8 h to form two
mainresveratrolmetabolites:monosulfateanddisulfate[41].
The eﬀect of resveratrol on HCC has been also extensively
studied. Bishayee et al. evaluated the inhibitory eﬀect of
resveratrol against hepatocarcinogenesis using a two-stage
HCC rat model. The HCC model was reproduced by a single
intraperitoneal injection of diethylnitrosamine (DENA),
followedbypromotionwithphenobarbitalindrinkingwater.
They found that resveratrol exerts a signiﬁcant chemo-
preventive eﬀect on DENA-initiated hepatocarcinogenesis
through inhibition of cell proliferation and induction of
apoptosis. They concluded the possible mechanism could be
that the resveratrol-induced apoptogenic signal is mediated
through the downregulation of Bcl-2 and upregulation of
Bax expression [42]. An in vitro s t u d yc a r r i e do u tb yS t e r v b o
et al. also showed that the inhibitory eﬀects of resveratrol
on cell proliferation and apoptosis in the HepG2 cells.
They found that resveratrol inhibited DNA synthesis and
increased nuclear size and granularity at G1 and S phases
of HepG2 cells. Apoptosis was also stimulated by resveratrol
in a concentration-dependent manner in HepG2 cells. They
concluded that resveratrol inhibits cell proliferation by
interfering with diﬀerent stages of the cell cycle, and causes
stimulation of apoptosis [43]. Notas et al. also used the
HepG2 cells to address the action of resveratrol on cell
growth and to examine some possible mechanisms. Their
results indicate that the stilbene resveratrol inhibits cell
proliferation, reduces the production of ROS and induces
apoptosis, through cell-cycle arrest in G1 and G2/M phases.
They also found that stilbene resveratrol modulates the
NO/NOS system, by increasing iNOS and eNOS expression,
NOS activity and NO production [44]. Yan et al. investigated
the eﬀects of resveratrol on proliferation and gap-junctional
intercellular communication (GJIC) in HepG2 cells. They
found that resveratrol arrests HepG2 cell growth in S phase,
inhibits DNA synthesis and induces cell apoptosis. The levels
of GJIC increased sharply after resveratrol treatment implied
that the increased GJIC level could play a role on the eﬀect of
resveratrol in the cancer chemopreventive activity [45]. The
study carried out by Ma et al. agreed with the observations
above. They further investigated the eﬀects of resveratrol
on mitochondrial membrane potential and cell morphology
of HepG2 cells. Their results showed that resveratrol at
high concentrations can obviously cause sharp increment
of the mitochondria membrane potential. They concluded
that the capacity of resveratrol for inhibiting proliferation
and inducing cell apoptosis could be resulted in depolarizing
mitochondrial membrane potential [46].
Like curcumin, potent anti-metastatic activity of resver-
atrol has been also investigated. Yu et al. investigated the
eﬀects of resveratrol on invasion ability of human HCC
cells and tumor necrosis factor-alpha (TNF-α)-mediated
MMP-9 expression. They found that resveratrol signiﬁcantly
inhibited TNF-α-mediated MMP-9 expression, NF-kappa B
expression and invasion in HepG2 cells. They concluded that
the inhibition of TNF-α-mediated MMP-9 expression and
the potential invasion by resveratrol are partly associated
with the downregulation of the NF-kappa B signaling path-
way [47] .S t u d i e sc a r r i e do u tb yM i u r ae ta l .d e m o n s t r a t e d
that dietary resveratrol can inhibit metastasis of hepatoma
in Donryu rats subcutaneously implanted with an ascites
hepatoma cell line of AH109A. They found that ROS accel-
erated the invasive capacity of a rat ascites hepatoma cells,
and resveratrol suppressed the ROS-potentiated invasion
of the hepatoma cells [48, 49]. Despite the encouraging
achievement regarding the anti-HCC eﬀects of resveratrol,
the low bioavailability and the potential toxicity by the
modulation of liver genes at the high dose are also observed
[50, 51]. Again, as with Curcumin the speciﬁc active agents
in resveratrol have not been accurately deﬁned, and clinical
trial researchers have been plagued by the lack of systemic
absorptionthatcanbeachievedthroughoraladministration.
2.1.3. Silibinin. Silibinin, a polyphenolic ﬂavonoid, is the
major biologically active compound of milk thistle. It is
well known that milk thistle is safe and well-tolerated, and
it protects the liver from drug or alcohol-related injury
[52, 53]. Silibinin and its crude form, silymarin, are used
clinically and as dietary supplements against liver toxicity.
A randomized controlled multicenter trial has shown that
daily administration of silymarin for several years results in6 Evidence-Based Complementary and Alternative Medicine
a signiﬁcant reduction in the mortality of patients suﬀering
from alcoholic liver cirrhosis [54]. Studies have demon-
strated the inhibitory eﬀects of silibinin on multiple cancer
cell lines including HCC [55, 56]. Varghese et al. investigated
the eﬀects of silibinin on cell growth, cytotoxicity, apoptosis
and cell cycle in two diﬀerent HCC cell lines, HepG2
(hepatitis B virus negative; p53 intact) and Hep3B (hepatitis
B virus positive; p53 mutated). They found that silibinin
strongly inhibited growth of both HepG2 and Hep3B cells.
Silibinin also caused G1 arrest in HepG2, and G1 and G2-M
arrests in Hep3B cells. Further studies showed that silibinin
induces Kip1/p27 but decreases cyclin D1, cyclin D3, cyclin
E, cyclin-dependent kinase (CDK)-2, and CDK4 levels in
these two cell lines. In Hep3B cells, silibinin also reduced
the protein levels of G2-M regulators. CDK2, CDK4, and
CDC2 kinase activity were strongly inhibited in these HCC
cells by silibinin [57]. Lah et al. investigated the eﬀect of
silibinin on HCC cell growth in four human HCC cell lines:
HuH7, HepG2, PLC/PRF/5 and Hep3B cells. After treated
with diﬀerent doses of silibinin, proliferation, apoptosis,
cell-cycle progression, histone acetylation and other related
signaltransductionswereexamined.Theydemonstratedthat
silibinin signiﬁcantly inhibited the growth of HuH7, HepG2,
Hep3B and PLC/PRF/5 human hepatoma cells. In addition,
they also found downregulated levels of metalloproteinase-
2 (MMP2) and CD34 in the HCC cells, which could be a
possible anti-angiogenic mechanism of silibinin. They also
demonstrated that silibinin increased acetylation of histone
H3 and H4 (AC-H3 and AC-H4), indicating a possible role
ofalteredhistoneacetylationinchemopreventionofsilibinin
against HCC cells [58]. Momeny et al. evaluated the eﬀect
of silibinin on HepG-2 cells regarding the biomarkers of
cell proliferation, cytotoxicity, metastatic potential, nitric
oxide (NO) production, ERK 1/2 phosphorylation and acti-
vation in HepG-2 cells. They found that silibinin inhibited
cell proliferation, matrix MMP-2 enzymatic activity, NO
production and ERK 1/2 phosphorylation without exerting
any cytotoxicity eﬀect. The possible mechanism of silibinin
against HCC could be inhibiting cell proliferation and
invasive potential of HepG-2 cells through inhibition of ERK
1/2 cascade [59].
Currently, silibinin has not been evaluated for human
eﬀects or toxicity in human clinical trials and thus only holds
potential promise as an active chemopreventitive agent.
2.1.4. Tanshinone II-A. Tanshinone IIA, one of the most
abundant diterpenes isolated from Salvia miltiorrhiza Bunge
(Danshen in Chinese). Tanshinone IIA has been shown
to possess pharmacological activities including antioxidant
[60], protecting and/or preventing angina pectoris and
myocardial infarction [61]. Report has shown that inhi-
bition of proliferation and cytotoxic eﬀects on cell lines
derived from various human carcinomas [62, 63]. Yuan
et al. evaluated the eﬀects of tanshinone II-A on growth
inhibition and apoptosis of human HCC cells (cell line
SMMC-7721). The growth and colony-forming of SMMC-
7721cells were obviously suppressed after tanshinone II-A
treatment. The apoptosis index was signiﬁcantly increased
and the cells were arrested in G(0)/G (1) phase. In addition,
expressions of apoptosis-related genes bcl-2 and c-myc
were downregulated, while fas, bax, p53 upregulated [64].
Zhong et al. investigated the eﬀect of tanshinone IIA on
the growth and apoptosis in HepG2 cells. They found that
tanshinone IIA not only inhibited the cell growth, but
also induced apoptosis in HepG2 cells [65]. Tang et al.
studies the eﬀect of tanshinone IIA on growth and apoptosis
in human HCC cell line BEL-7402. Growth suppression
and induced cell apoptosis were found as BEL-7402 cells
treated with tanshinone IIA [66]. Wang et al. evaluated the
proliferation of human HCC cell line (SMMC-7721) treated
with tanshinone by Brdu labeling and PCNA immunohis-
tochemical staining. They found decreased indexes of Brdu
labeling and PCNA detection after tanshinone treatment.
The inhibitory eﬀect of tanshinone on cancer cell growth
might associate with inhibiting DNA synthesis [67, 68]. Li
et al. performed in vitro and in vivo studies using polylactic
acid nanoparticles containing tanshinone IIA (TS-PLA-NPs)
against HCC. They found that tanshinone IIA in TS-PLA-
NPs were eﬀective in destroying the human liver cancer cells.
TanshinoneIIAinTS-PLA-NPsalsopreventedtumorgrowth
and increased survival rate of mice with hepatoma [69].
2.1.5. Other Reported Compounds. Beside these widely inves-
tigated compounds, some other potential compounds for
the chemopreventive eﬀect against HCC have been also
evaluated. Salvianolic acid B is a major water-soluble
polyphenolic acid extracted from Radix Salviae miltiorrhizae
(Sm). Studies have shown that Salvianolic acid B can
improve acute and chronic liver, decrease the serum ala-
nineaminotransferase(ALT)andaspartateaminotransferase
(AST) levels and enhance the total prostaglandin content
in liver mesenchymal cells in injured rats [70]. Baicalein
is a ﬂavonoid from baikal skullcap root. Matsuzaki et al.
investigated the anti- HCC eﬀect of baicalein. They found
that treatment with baicalein strongly inhibited the activity
of topoisomerase II, induced apoptosis and suppressed the
proliferation the HCC cell lines [71]. Pheophorbide a (Pa)
is an active compound from Scutellaria barbata.T a n ge ta l .
usedamulti-drugresistant(MDR)HCCcellline(R-HepG2)
to evaluate the anti-proliferative eﬀect of Pa. They found
that Pa can signiﬁcantly inhibit the growth of R-HepG2 cells
[72]. It has been showed that Pa can enhance the eﬃcacy of
photodynamic therapy (PDT) for HCC, very likely due to its
antiproliferative and pro-apoptotic eﬀect [73–75].
2.2. Herbal Composite Formula. Besides these promising
molecule compounds isolated or derived from herbals, there
is a number of herbal complex formulas prescribed by
Chinese medicine practitioners deﬁned as either a tradi-
tional medical doctor or an herbal pharmacists for treating
and preventing HCC. Using state-of-the-art technology,
the techniques of herbal extraction and puriﬁcation have
been dramatically improved and innovated in the Chinese
herbal medicine industry. The traditional forms of herbal
preparation such as decoction, powder, plasters and pill have
been developed into the modern forms, capsules, tabletsEvidence-Based Complementary and Alternative Medicine 7
and injection which as more convenient and palatable. The
technological improvement of herbal preparation also made
itbecomingpossibleforbettercontroltheconstituentsofthe
herbal composite formula.
Although some herbal composite formula showed eﬃ-
cacy against HCC, it is worth mentioning that the usage
of herbal composite formula is from the herbal medicine
practitioner’s point of view which is quite diﬀerent from
that of conventional Western medicine, that is, not validated
in a standard Phase 1, Phase 2 or Phase 3 clinical trials.
When a formula is composed using diﬀerent herbs, from the
herbal medicine principle, the whole unhealthy condition
should be treated to make body homeostasis other than to
“cure” tumor only. Generally, herbal composite formula can
bedividedintotwocategories:classiccompositeformulaand
experience composite formula. Classic composite formula is
an ancient formula with deﬁnite constituent of herbs. Classic
composite formula can be traced back as far as thousands
years,whileexperiencecompositeformulaisacontemporary
composite formula which is generally modiﬁed from classic
composite formula. Experience composite formula is usually
not with deﬁnite constituent of herbs, and the constituent of
composite formula can be changed with addition or deletion
of herbs according to the symptoms of patients. Both classic
composite formula and experience composite formula are
discussed and summarized in Table 2.
2.2.1. Clinical Studies of Classic Herbal Composite Formula.
Shi-Quan-Da-Bu-Tang (TJ-48, Juzen-taiho-to in Japanese,)
is a classic herbal composite formula. It consist of 10
herbs; Mongolian milkvetch root, Cinnamon, ginseng root,
largehead atractylodes rhizome, tuckahoe, liquorice root,
Chinese angelica, radix rehmanniae root, white peony root,
szechwan lovge rhizome. TJ-48 has been used extensively in
medical practice in Asia even though their mechanism of
action remains elusive. Tsuchiya et al. studied the protective
eﬀect of TJ-48 against hepatocarcinogenesis in HCC patients
after surgical treatment. A signiﬁcantly longer intrahepatic
recurrence-free survival was observed in the TJ-48 group
even though most of the patients experienced recurrence of
HCC [87].
Xiao-Chai-Hu-Tang (TJ-9, Sho-saiko-to in Japanese), a
classic herbal composite formula, is commonly administered
to patients with chronic viral liver disease in order to
improve their overall physical condition and to prevent
the development of liver cancer. The crude extracts of TJ-
9 consist of seven herbs: bupleurum root, pinellia tuber,
scutellaria root, jujube fruit, ginseng root, glycyrrhiza root
and ginger rhizome. A prospective, randomized, non-blind
controlled study was carried out by Oka et al. to evaluate the
preventiveeﬀectofTJ-9onHCCdevelopment.Twohundred
and sixty patients with cirrhosis were randomly assigned to
two groups, matched for age, sex, presence of hepatitis B
surface antigen and the severity of liver damage. The patients
in the trial group were given TJ-9 at a daily oral dose of 7.5g
in addition to the conventional drugs given to the control
patients, and prospectively monitored for 60 months. They
found that the survival curve for 5 years of the trial group
withoutHepatitisBantigenwassigniﬁcantlyhigherthanthat
of the control group. They concluded that TJ-9 could help to
prevent the development of HCC in patients with cirrhosis,
particularlyinpatientswithnegativehepatitisBantigen[76].
TheﬂawinthisstudywasthatthehepatitisBantigenpatients
were a subset analysis and the study was underpowered and
atriskforatype1erroriniteﬃcacywithhepatitisBpatients.
A study from the same group further evaluated the potential
of TJ-9 against HCC in pairs of patients matched for age,
sex, presence of hepatitis B antigen and the scores of the
severityofliverdysfunctionfrom260cirrhoticsubjects.They
found the incidence of HCC was signiﬁcantly lower in the
trial group, 17 HCC patients in the control versus 9 HCC
patients in the trial group. They concluded that TJ-9 may
prevent or delay the emergence of latent HCC in patients
withcirrhosis[88].Thelimitationofthisstudyistheconcern
for duplication of patients studied. These results came from
the same authors, over the same time interval, and there is
no mention that these two groups of patients were diﬀerent.
Thus while TJ-9 may hold promise, further regulated studies
are needed beyond a single institutional study to validate this
initial encouraging results.
Bu-Zhong-Yi-Qi-Tang (BZYQT) is a classic herbal com-
posite formula in Chinese herbal medicine, it consist of eight
herbs; Mongolian milkvetch root, liquorice root, largehead
atractylodes rhizome, ginseng root, Chinese angelica, skunk
bugbane rhizome, bupleurum root and tangerine. Kao
et al. investigated the eﬀects of BZYQT on granulocyte
colony-stimulating-factor (G-CSF) and TNF-α production
by peripheral blood mononuclear cells (PBMC) in healthy
volunteers and HCC patients. They found that the produc-
tions of G-CSF and TNF-α in PBMC of both volunteers and
HCC patients were signiﬁcantly stimulated by BZYQT. How-
ever, the increments of G-CSF and TNF-α in HCC patients
are not as high as in healthy volunteers. They suggested that
BZYQT is a unique formula for the stimulation of PBMC to
produceG-CSFandTNF-α,andadministrationwithBZYQT
may be beneﬁcial for increasing defensive mechanism in
patients against HCC [81]. The limitations of this study are
the lack of pharmacokinetic distribution of BZYQT eﬀects in
HCC patients, which may be its major limitations in a larger
clinical evaluation.
2.2.2. Clinical Studies of Experience Herbal Composite For-
mula. Because the focus of composing a formula is not
in the direct “killing” of tumor cells, herbal composite
formula is usually considered as palliative treatment and
adjuvant treatment for HCC. The purpose for clinical use
of experience herbal composite formula is to recover liver
function, alleviate symptoms and to improve life quality.
Most studies of use of experience herbal composite formula
are retrospective, and the constituent of herbs in composite
formulaisnotwelldeﬁned.Theexperienceherbalcomposite
formula usually combines with the conventional palliative
treatment such as transcatheter arterial chemoembolization
(TACE) and systemic chemotherapy (Table 3).
A retrospective study was undertaken by Chen et al. to
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Table 2: Summary of anti-HCC herbal composite formula.
Herbal composite formula Possible mechanisms of anti-HCC References
Shi-Quan-Da-Bu-Tang (TJ-48) Inhibits tumors growth, reduces oxidative DNA damage, inﬂammatory cell inﬁltration
and cytokine expression [76]
Sho-saiko-to (TJ-9) Increases TNF-α and G-CSF; inhibits 8-OHdG formation; reduces the number of
pre-neoplastic cells; cell-killing eﬀect [77–80]
Bu-Zhong-Yi-Qi-Tang Stimulates productions of G-CSF and TNF-α [81]
Shenqi mixture (SQM) Increases CD3+,C D 4 +,C D 4 +/CD8+,N Ka c t i v i t y [ 82]
Xiaoliu Pingyi Mixture (XLPY) Inhibits growth; induces apoptosis; inhibits Bcl-2 gene [83]
Sihoga-Yonggol-Moryo-Tang
(SGYMT) Inhibits MMP-2 and MMP-9; inhibits tumor invasion [79]
QHF Inhibits the growth of HCC [84]
Fuzheng Jiedu Decoction (FJD) Enhances PTEN; inhibits tumor invasion [85]
Star-99 Inhibits the growth of HCC; induces apoptosis [86]
Table 3: Summary of clinical reports using herbal medicines to treat patients with HCC.
Classic herbal composite
formula
Patient numbers
(treated/control) Dosing and duration The anti-HCC eﬀects Refs
Shi-Quan-Da-Bu-Tang
(TJ-48) 48 (10/38) 7.5g daily oral dose. For up
to 6 years
Inhibiting tumors growth. Improving
intrahepatic recurrence-free survival after
surgical treatment of HCC
[76]
Sho-saiko-to (TJ-9) 260 (130/130) 7.5g daily oral dose. For up
to 2.5 years
Preventing the development of HCC in
patients with cirrhosis, particularly in
patients with negative HBs antigen
[77, 79]
Shenqi mixture (SQM)
combined with microwave
coagulation
72 (36/36) 20ml, three times a day for
1m o n t h
Improving clinical symptoms and the
quality of life. Prolong the survival period
of patients
[82]
Experience herbal composite
formula
Complex prescription of
Chinese crude drug after
TACE therapy
82 (45/37) Dosing unavailable.
Duration 1 month
Reducing the side eﬀect of TACE.
Improving liver function and life quality [89]
Complex prescription of
Chinese crude drug
combined with TACE
therapy
2653
(unavailable/unavailable)
Dosing and duration
unavailable
Improving patient survival and life
quality. Alleviating symptoms. Increasing
tumor response
[82]
Complex prescription of
Chinese crude drug
combined with
chemotherapy
2079
(unavailable/unavailable)
Dosing and duration
unavailable
Improving survival rate and tumor
response [90]
drug on the hepatic function and some symptoms in HCC
patients post-TACE. Forty-ﬁve HCC patients post-TACE
were treated with a complex prescription of herbal crude,
other 37 patients as the control group treated by routine
therapy. The symptoms such as anorexia, nausea, abdominal
distention and lassitude along with liver function and α-
fetoprotein (AFP) were observed. At the end of the therapy,
both symptoms and hepatic function were improved. They
concluded that the complex prescription of Chinese crude
drug could beneﬁt for HCC patients post-TACE by the
recoveryofliverfunctionandimprovementofthelifequality
[91].
Meng et al. performed meta-analysis to compare the
eﬃcacy and safety of complex prescription of Chinese crude
drug plus TACE (therapy I) with that of TACE alone
(therapy II). In total, in 37 trials involving 2653 patients,
the results showed that therapy I, compared with therapy
II, improved patient survival, quality of life, alleviated
symptoms and increased tumor response. Combining of
complex prescription of Chinese crude drug with TACE
are thus more therapeutically beneﬁcial. No serious adverse
events were reported in therapy I group [89].
Shu et al. evaluated the eﬀectiveness of Chinese herbal
medicine combined with chemotherapy. They searched the
databases TCMLARS, PubMed and EMBASE as well as the
bibliographies of studies identiﬁed in the systematic search
for potentially relevant titles or abstracts of studies in any
language. They applied random eﬀects meta-analysis in 26Evidence-Based Complementary and Alternative Medicine 9
studies representing 2079 patients met the inclusion criteria.
They found that Chinese herbal medicine combined with
chemotherapy improved survival rate and tumor response
compared with chemotherapy alone [90].
Shenqi mixture (SQM) is an herbal composite formula
from Ginseng root and Mongolian milkvetch root. Lin et
al. investigated the short-term eﬃcacy and safety of SQM
combined with microwave coagulation in treating primary
HCC. Tumor size, patients’ symptoms, serum level of AFP,
and some immune parameters were evaluated. The results
indicated that SQM decreased tumor size and AFP. The
levels of CD3+,C D 4 +,C D 4 +/CD8+, NK activity, Karnofsky
scores and hepatic function were improved with SQM plus
microwave coagulation treatment compared to those in
the microwave coagulation alone. SQM also improved the
survival rate and symptoms such as hepatic region pain,
fever, weakness, poor appetite and jaundice [82].
2.2.3. Experimental Studies of Herbal Composite Formula
Cell Culture Studies. The in vitro anti-HCC activity of herbal
composite formula with either indeﬁnite constituent or
deﬁnite constituent has been studied widely. Chao et al.
investigated the eﬀect of the extracts from Lycium barbarum
(LBE) and Rehmannia glutinosa (RGE) on the cell prolif-
eration and apoptosis in both rat (H-4-II-E) and human
(HA22T/VGH) HCC cells. They incubated these two HCC
cell lines with various concentrations of LBE and RGE, and
measured the cell proliferation, apoptosis and p53 protein.
They found that both LBE and RGE inhibited proliferation
of H-4-II-E cells and of HA22T/VGH cells. Apoptosis and
p53 signiﬁcantly were increased in H-4-II-E cells treatment
with crude LBE and RGE [92]. Chang et al. studied the
chemopreventive potential of the extract of Cornus oﬃcinalis
Sieb.etZuceagainstHCCusingthreeHCCcelllines(HepG2,
SK-Hep1 and PLC/PRF/5). We discuss C. oﬃcinalis Sieb.
et Zuce as herbal composite formula for the following
two reasons. First, according to Chinese herbal medicine,
sometimes single herb can be a composite formula, that is,
Ginseng Decoction is content of only ginseng. Secondly, C.
oﬃcinalisSieb.etZuce is not a single compound. There could
be hundreds compounds in the extracts of C. oﬃcinalis Sieb.
etZuce.Chang et al.foundthatextractof C.oﬃcinalisSieb.et
Zuce inhibited growthinalltheseHCCcells.Theyconcluded
that C. oﬃcinalis Sieb. et Zuce might be a candidate for
chemopreventiveagentagainstHCCthroughanti-neoplastic
eﬀects [93]. Li et al. investigated Xiaoliu Pingyi Mixture
(XLPY) induced apoptosis in human HCC cell line H-7402.
Instead of directly adding herbal agent into culture media,
they used serum pharmacologic method, serum loaded with
herbal ingredients to treat cells. They found that XLPY
loaded serum can signiﬁcantly inhibit HCC cell growth and
induce apoptosis. Bcl-2 gene expression was also inhibited in
H-7402 cells treated with XLPY [83].
TJ-9, as a typical classic composite formula, has been
investigated regarding its anti-HCC eﬀect. The ingredients
from this classic composite formula have been also evaluated
widely to explore more eﬃcient l compounds against HCC.
Yamashiki et al. investigated the eﬀect of TJ-9 on TNF-α
and G-CSF in peripheral mononuclear cells of patients with
HCC accompanied by liver cirrhosis. They found that TJ-9
can increase the levels of TNF-α and G-CSF. They concluded
that TJ-9 could enhance the biological defense mechanism
throughincreasingTNF-αandG-CSFtherebyimprovingthe
overall physical condition in HCC patients [94]. Okita et
al. investigated the ingredients of TJ-9 (baicalein, baicalin,
saikosaponin-a, saikosaponin-c, ginsenoside Rb1, ginseno-
side Rg1) on cultured human hepatoma cells (HuH-7). Cell-
c y c l ea n a l y s i sw a sc a r r i e do u tw i t hﬂ o wc y t o m e t r ya n dt h e
bromodeoxyuridine (BrdU)-labeling method. They found
that baicalein, baicalin and saikosaponin-a inhibited cell
proliferation dose-dependently. In addition, saikosaponin-a
possesses a strong cell-killing eﬀect, however, saikosaponin-
c, ginsenoside Rb1 and ginsenoside Rg1 had no eﬀect on cell
proliferation [77]. Yano et al. compared the individual ingre-
dients (saikosaponin a, c and d, ginsenoside Rb1 and Rg1,
glycyrrhizin, baicalin, baicalein and wogonin) from TJ-9 to
TJ-9 composite formula using a human HCC cell line (KIM-
1). They found that TJ-9 composite formula suppressed
signiﬁcantly the proliferation of KIM-1cells compared with
any individual ingredient from TJ-9 composite formula. TJ-
9 composite formula reduced the number of preneoplastic
cells [78].
Chai-Hu-Jia-Long-Gu-Mu-Li-Tang (SGYMT; Saiko-ka-
ryukotsu-borei-to in Japanese; Sihoga-Yonggol-Moryo-Tang
in Korean) is a classic composite formula. The crude extracts
of SGYMT consist of 11 herbs: bupleurum root, dragon’s
bone, rhubarb, pinellia tuber, scutellaria root, cassia twig,
rhubarb, jujube fruit, ginseng root, glycyrrhiza root and
ginger rhizome. Ha et al. studied the extracts prepared
from SGYMT and its herbal ingredients for the inhibitory
eﬀects on tumor-speciﬁc matrix metalloproteinases-2 and -9
(MMP-2/9) activities in HCC cell line (SK-Hep1 cells). They
found that SGYMT decreased the activities of MMP-2 and -
9. However, the cytotoxicities of SGYMT and its ingredients
on SK-Hep1 cells were very low. The inhibitory eﬀect on the
invasion of SK-Hep1 cells using matrigel precoated transwell
chambers showed that SGYMT eﬀectively inhibited the
invasion ofSK-Hep1 cellsascomparedtothecontrolgroups.
TheyconcludedthatSGYMTcouldbeusedaspotentialanti-
tumor metastasis agent [79].
Animal Model Studies. QHF is an herbal composite formula
including three category herbs (according to Chinese herbal
principle), in which Q (Qingrejiedu) represents “clean up
pathogenic and toxic materials”; H (Huoxuehuayu) repre-
sents “improve micro blood circulation”; and F (Fuzheng-
guben) represents “enhance defending capability”. QHF
consistofmainlybyGinsenosidesRg3,Lentinan,Tanshinone
and Norcantharidin. Chen et al. investigated the active
ingredients in QHF formula against HCC. They observed
the anti-HCC eﬀect of QHF combined with cisplatin in a
HCC cells implanted mouse model. The results indicated
that treatment with the QHF formula was eﬃcient not only
in inhibiting the growth of HCC cells, but also in prolonging
the life of the HCC mice. In addition, QHF combined with
cisplatin can ameliorate cisplatin-induced leucopenia, spleen
and thymus atrophy and other toxic reactions [84].10 Evidence-Based Complementary and Alternative Medicine
Yin et al. investigated the eﬀect of Fuzheng Jiedu Decoc-
tion (FJD), an experience composite formula, against HCC
using male BALB/c athymic mouse model. They observed
survival rate, volume of tumors, and intrahepatic metastasis.
TheresultsindicatedthatFJDsigniﬁcantlyincreasedthetotal
survival rate and decreased tumor intrahepatic metastasis.
Immunohistochemistry showed that an increased intensity
of phosphatase and tensin homolog deleted on chromosome
ten (PTEN) staining in tumor tissue treated with FJD. They
concluded that FJD can prolong the survival and decrease
tumor intrahepatic metastasis. The possible mechanisms of
FJDagainstHCCcouldbethroughenhancingtheexpression
of PTEN in the compromised liver [85].
Lin et al. investigated the anti-cancer eﬀect by tumor
focal injection of Chinese herbal composite formula Star-
99 in a HCC mouse model. Nude mice transplanted with
human HCC SMMC-7721cells were intratumorally injected
with Star-99 every 5 days with a total of four injections.
Tumor value, growth index and apoptosis were evaluated.
They found that Star-99 can decrease the tumor size, and
increase apoptotic index signiﬁcantly. They concluded that
Star-99 markedly destructs HCC cellsin vivo and it is feasible
in the treatment of HCC [86].
Qian et al. used Bletilla striata as TACE agent to treat
HCC rats. Bletilla striata was milled into a micro-particle
(diameter 45μm), and rat HCC model was induced by
hepatic implantation with hepatoma cells. They found that
application of B. striata combined with mitomycin using
TACE inhibited the growth of tumor which implanted in
the liver. Importantly, the survival rate of HCC rats was also
signiﬁcantly improved. They concluded that B. striata could
be a valuable anti-HCC as a TACE agent [95].
There are some in vivo studies regarding the classic
herbal composite formula. Tsuchiya et al. performed a DEN
induced HCC mouse model to evaluate the eﬀect of TJ-
48 on HCC. They found that TJ-48 inhibited the devel-
opment of liver tumors along with the reduced oxidative
DNA damage, inﬂammatory cell inﬁltration and cytokine
expression[87].Shiotaetal.investigatedthepreventiveeﬀect
of TJ-9 on hepatocarcinogenesis using a DEN-induced HCC
rat model. They found that TJ-9 reduced the number of
preneoplastic cells, detected as the glutathione S transferase
P (GST-P)-positive hepatocytes, inhibited the development
of liver tumors, and signiﬁcantly decreased the formation of
8-hydroxy-2 -deoxyguanosine (8-OHdG). They concluded
that TJ-9 prevents hepatocarcinogenesis in association with
inhibition of 8-OHdG formation [96]. Although TJ-9 has
been showed encouraging eﬀect for anti-HCC in most
studied in clinical patient and cell culture, some disagree-
ment also exist. Watanabe et al. investigated the outcome
of administration of TJ-9 on the occurrence of hepatic
neoplasia in Long-Evans Cinnamon rats, a spontaneous
HCCmodel.TJ-9wasadministeredfrom6weeksofageuntil
the rats were sacriﬁced at 76 weeks, at which time most of
the non-treated animals were known to have HCC. However,
in regard of HCC, the percent area, number of areas, and
mean size of area staining positively for GST-P revealed
no signiﬁcant diﬀerences between the groups. The number
of GST-P-positive areas within the HCC lesions was even
greaterintheTJ-9groupthaninthecontrol.Theyconcluded
thatlong-termadministration ofTJ-9didnotreducetherisk
of hepatocarcinogenesis in LEC rats [80].
3. FutureStudy andSafety
Through centuries of clinical practices in herbal medicine,
there could be a number of candidate drugs derived from the
herbs or herbal composites formulae for chemoprevention
and chemotherapeutic strategy against HCC. Certain herbal
compoundsandherbalcompositeformulahavebeenstudied
through in vitro and in vivo as an anti-HCC agent for
many years, enhancing our knowledge about their biologic
functions and targets. Despite studies for decades as well as
advancement of our understanding of the molecular targets,
there are still some concerns of herbal medicine. The ﬁrst is
the use of composite formula (usually mixed extracts with
uncertain ingredients) could result in dramatically diﬀerent
outcome for clinical trials and experimental studies. To
address this issue, the biologically active substances in herbs
need to be deﬁned and standardized. Simplifying the herbal
compounds to several biologically active compounds could
be a way to standardized clinical trails and experimental
studies. However, the biologically active eﬀects of herbal
composite formulas could be from the interactions between
herbs and compounds, and one should be cautious to
avoid eliminating the compound(s) within from the herbal
composite formula even though the compound(s) may not
have any biologically active eﬀect by themselves (itself). The
second issue is the relationship between clinical studies and
experiments in test tubes and in animals. Many clinical
trials in China focusing on the anticancer eﬀects of herbal
composite formulas have been conducted. There is a lack
of randomized, placebo-controlled clinical studies regarding
the use of both herbal compounds and composite formula.
High-quality, rigorously controlled clinical trials are needed
to avoid the overstated eﬀect of herbal compounds and
composite formula. On the other hand, these clinical trials
provided some clues to further investigate the pharma-
cological eﬀects of the herbal compounds and composite
formula being used “eﬀective” against HCC, which only
can be demonstrated deﬁnitively by the scientiﬁc data. Thus
future clinical trials should evaluate a dedicated deﬁned
reproducible herbal compound to allow for standardizing
therapy and eﬃcacy.
The third is concern about the safety of herbal remedies.
Traditional medical doctor, or herbal pharmacists recom-
mendthetraditionalformsofherbsthatareorganic,unadul-
terated, unprocessed and prepared in traditional ways, just
like any dietary ingredient, the processing methodologies
are described in Chinese, Japanese, Korean Pharmacopoeias.
They simply trust the wisdom of the body to recognize and
make use of herbs. However, the reports of the herbal toxic
eﬀects contradict the popular view that herbals are natural
and harmless. Among the herbal toxic eﬀects, hepatotoxicity
is the most frequent. The investigation of compounds and
composite formula regarding safety and toxicity is needed
before deﬁnitive clinical guidelines can be made.Evidence-Based Complementary and Alternative Medicine 11
Thus in summary herbal compounds have been shown
to be eﬃcacious and safe in small single center studies in the
treatment and prevention of HCC and cirrhosis. However,
on going standardization of the preparation, purity, and
active compounds in conjunction with natural constituents
should be speciﬁed for quality control aspects and must be
established in order for future Phase 2 and Phase 3 trials can
be created to verify these intriguing and optimistic results in
this devastating disease.
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